Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68085 | 0.86 | PAX8 (0.42) | SSTR4CLK1BACE1PAX8HTR1A | |
| SCHEMBL959885 | 0.84 | GRM5 (0.38) | PAX8SYKGRM5MEN1RAB9A | |
| SCHEMBL2248255 | 0.83 | SSTR4 (0.36) | SSTR4BACE1PAX8HTR1ASYK | |
| SCHEMBL24136431 | 0.83 | PAX8 (0.34) | SSTR4PAX8SYKMEN1NPC1 | |
| SCHEMBL26332181 | 0.83 | PAX8 (0.34) | SSTR4PAX8SYKMEN1NPC1 | |
| SCHEMBL10261793 | 0.82 | USP30 (0.39) | SSTR4CLK1BACE1PAX8HTR1A | |
| SCHEMBL960170 | 0.82 | SSTR4 (0.34) | SSTR4PAX8SYKMEN1NPC1 | |
| SCHEMBL13447982 | 0.81 | KDM4E (0.47) | PAX8SYKMEN1NPC1RAB9A | |
| SCHEMBL19477815 | 0.80 | SSTR4 (0.35) | SSTR4PAX8SYKMEN1NPC1 | |
| SCHEMBL20388075 | 0.80 | SYK (0.36) | SSTR4PAX8SYKCHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055108-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | HUTCHMED LTD (CN) | 2026-02-26 | — | — | US | disclosed |
| CN-117917406-A | Heterocyclic compounds, process for their preparation and their use | 四川科伦博泰生物医药股份有限公司 | 2024-04-23 | — | — | CN | disclosed |
| US-20230136073-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORPORATION (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20230136073-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORPORATION (JP) | 2023-05-04 | — | — | US | disclosed |
| EP-3954686-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | Calithera Biosciences, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3050878-B1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORP (JP) | 2021-10-27 | — | — | EP | disclosed |
| US-20210292289-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. | 2021-09-23 | — | — | US | disclosed |
| EP-3858824-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-2920168-B1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES INC (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3363797-B1 | ORAL DOSAGE FORM OF APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-8552196-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| WO-2013104573-A1 | PYRIDAZINE AMIDE COMPOUNDS AND THEIR USE AS SYK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013104575-A1 | THIENOPYRIMIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-18 | — | — | WO | disclosed |
| US-20130178478-A1 | PYRIDAZINE AMIDE COMPOUNDS | HOFFMAN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178460-A1 | THIENOPYRIMIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8378108-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20130035339-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130012521-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| WO-2012076989-A1 | KETOLIDE COMPOUNDS | WOCKHARDT LIMITED (IN) | 2012-06-14 | — | — | WO | disclosed |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136073-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | SLC39A3, SLC39A14, SLC39A11 | SSTR4 1325/4885CLK1 2142/4885BACE1 2370/4885 |
| US-20130178478-A1 | PYRIDAZINE AMIDE COMPOUNDS | SYK, BTK, IRAK2 | SSTR4 1944/4885CLK1 3219/4885BACE1 4027/4885 |
| US-20210292289-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | GLS, GLS2, GLUL | SSTR4 1551/4885CLK1 2385/4885BACE1 1200/4885 |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, AIFM1 | SSTR4 4414/4885CLK1 1008/4885BACE1 863/4885 |
| US-20130178460-A1 | THIENOPYRIMIDINE COMPOUNDS | SYK, BTK, LCK | SSTR4 2560/4885CLK1 3880/4885BACE1 3388/4885 |
| US-20260055108-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | CBR1, CNR1, CBR3 | SSTR4 80/4885CLK1 2432/4885BACE1 1843/4885 |
| US-20130035339-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, MAP3K6 | SSTR4 4328/4885CLK1 884/4885BACE1 941/4885 |
| US-20130012521-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | SSTR4 4449/4885CLK1 942/4885BACE1 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.